Taken together, our study reveals a novel therapeutic strategy involving the use of a CHK1 inhibitor to elicit a broad DNA damage response as an immunomodulatory agent in ARID1A-deficient CRC tumors, which overcomes the current challenges associated with ICBs in CRC patients. The gene discussed is ARID1A; the disease is colorectal carcinoma.